Laidlaw started coverage on shares of VBI Vaccines Inc. (NASDAQ:VBIV) in a research report sent to investors on Monday. The brokerage issued a buy rating and a $6.00 price objective on the biopharmaceutical company’s stock.
Separately, Ladenburg Thalmann assumed coverage on shares of VBI Vaccines in a research note on Tuesday, July 26th. They issued a buy rating on the stock.
Shares of VBI Vaccines (NASDAQ:VBIV) opened at 3.21 on Monday. VBI Vaccines has a one year low of $3.07 and a one year high of $7.80. The company’s 50 day moving average is $3.66 and its 200 day moving average is $3.81. The company’s market cap is $115.99 million.
An institutional investor recently raised its position in VBI Vaccines stock. BlackRock Fund Advisors raised its position in shares of VBI Vaccines Inc. (NASDAQ:VBIV) by 1,701.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,789 shares of the biopharmaceutical company’s stock after buying an additional 42,303 shares during the period. BlackRock Fund Advisors owned 0.14% of VBI Vaccines worth $177,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.26% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.